It is possible that albumin does bind direct-reacting and indirect-reacting bilirubin with greater affinity than serum globulins but becomes saturated at relatively low bilirubin concentrations.

EPO grants Sonnet EU Patent No. EP3583125 B1 for Fully Human Albumin Binding (FHAB®) domain fusion proteins, expanding global IP protection.

Citius Oncology, Inc. (NASDAQ:CTOR) saw its stock rise 4.1% after announcing a new distribution services agreement with Cencora to broaden the reach of its FDA-approved immunotherapy, LYMPHIR. The ...

To investigate the stereoselective binding of mexiletine or ketoprofen enantiomers with different recombinant domains of human serum albumin (HSA). Three domains (HSA DOM I, II and III) were ...

The interest in albumin binding also arises from the prospective use of drug delivery systems based on albumin nanoparticles.

Albumin is the main transport protein in blood plasma and can bind to a wide variety of molecules. Albumin has a two-domain structure with at least two high-affinity and several low-affinity binding ...

Nanoparticles (NPs) are materials whose dimensions range from 1 to 1,000 nanometers (nm). Due to their nano-scale dimensions and tunable material properties, NPs have gained interest in the global ...

FcRn protects IgG and albumin from catabolism, transports IgG across the placenta, and regulates IgG function. Blocking or augmenting FcRn can decrease autoimmune antibodies and enhance drug delivery.

Tiny amounts of proteins like albumin can be found in your urine, but albumin levels above a certain threshold are a sign that your kidneys aren't working properly. Learn more.

PD-L1 is the target of several clinically approved cancer immunotherapies. By linking the STING agonist to this bivalent nanobody – with one end binding to albumin and the other to PD-L1 – they found ...

Albumin boosted zinc and C-peptide binding to MS red blood cells, and this effect went away with interferon beta treatment.